Contexto sectorial
Axsome Therapeutics Inc [AXSM]
Última actualización 24 Jun 2026 @ 16:00 (Exchange is closed)
Último: $237.92
-1.67%
2.65
GaG Algo Score™
v1.0
Corto
2.65
Medio
4.26
Largo
3.89
COMPRAR
73.47%
rentabilidad 30.87%
VENDER
68.00%
rentabilidad -14.34%
Línea
Datos pivot
Estadísticas pivot
| Métrica | Promedio | Mediana | Desv. est. |
|---|---|---|---|
| Ganancia % | 14.86% | 14.86% | 0.00% |
| Pérdida % | N/A | N/A | N/A |
| Duración | 10.0d | 10d | 0.0d |
| Pivots encontrados | 2 |
| Tramos ganancia/pérdida | 1 (1 Ganancia / 0 Pérdida) |
| Último pivot | Top @ $255.17 el 2026-06-12 |
| Cambio desde el último pivot | $-13.20 (-5.17%) |
Predicción del próximo pivot Último: $237.92
| Próximo tipo previsto | N/D |
| Precio previsto (prom.) | N/A |
| Precio previsto (mediana) | N/A |
| Rango de precio previsto (~68%) | N/A |
| Cambio al objetivo promedio | N/A (N/A) |
| Fecha prevista (prom.) | 2026-06-22 |
| Rango de fechas previsto (~68%) | 2026-06-22 - 2026-06-22 |
| Base | Insufficient historical loss data for prediction. and duration (Avg: 10.0 days, StdDev: 0.0 days) |
| Nota | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
Moderate loss for Axsome Therapeutics Inc on Tuesday.
Axsome Therapeutics Inc (AXSM) stock price saw a concerning drop on Tuesday after the stock fell $-5.88 (-2.37%) from the previous session on very high volume. The stock fell slightly more than the NASDAQ which was down -0.43%.(The stock has fallen 3 days straight.This prolonged decline suggests potential for a price bounce) Yesterday's trading volume was 1.24M shares, worth about $300.92M. This represents 429 490 shares more than the day before. Volume was above the 10-day average of 685 470 shares.
Axsome Therapeutics Inc signals
There is no conclusive signals given from RSI. The price is above both the short- and long-term averages, and the short-term average is above the long-term average, confirming an established up-trend. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (36.7%), medium- (36.7%), and long-term (36.7%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
Axsome Therapeutics Inc Support & Resistance Levels
The stock is approaching the closest resistance level at $242.00. approximately $0.0300 (0.01%) away. Reacting down from resistance. Breaking above this level could signal further upside where next resistance level will be found at $246. On a fall back there will be support at $112 The dis das resistance s1112 -
Axsome Therapeutics Inc Evaluation
- Corto puntuación: 2.65
- Medio puntuación: 4.26
- Largo puntuación: 3.89
Flujo de propiedad
GetAGraph InsiderPower
Transacciones
154
Fuerza compradora
176.97M
Fuerza vendedora
126.87M
Fiabilidad
97/100
Compra / venta
1.39
Corr. hist.
0.08
Última señal
Buy 2026-06-23
Officer 98
Director 56
2026-06-10
Jeffs Roger Director
Sell 286
2026-06-10
Coleman Mark Director
Sell 643
2026-06-09
Mahony Susan Director
Sell 300
2026-06-09
Tabuteau Herriot Officer
Buy 49 670
2026-06-09
Pizzie Nick Officer
Buy 33 000
2026-06-08
Jeffs Roger Director
Buy 1 429
Mapa de relación
Resumen de correlación
<span style="background-color: lightgreen">Undervalued: <i class="arrow arrow-up"></i>0.85% <strong>$239.56</strong> paired level.</span>
Positioning pressure
Short interest pressure
Short interest
6.14%
Of outstanding shares
Short float
7.28%
Of tradable float
Days to cover
4.99
Short interest divided by average volume
Squeeze probability
22.00%
+11.38% change
Short interest is worth monitoring, but the setup is not extreme.
Updated 2026-05-29Earnings quality
Earnings history
Reported quarters
10
EPS beats
8
EPS misses
2
Avg. surprise
18.18%
| Period | Date | Actual EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q3/2025 | 2025-11-10 | - | - | - | - |
| Q2/2025 | 2025-08-04 | - | $-1.070 | - | - |
| Q1/2025 | 2025-05-05 | $-0.800 | $-1.260 | 36.51% | 121.46M |
| Q4/2024 | 2025-02-18 | $-0.960 | $-1.000 | 4.00% | 118.77M |
| Q3/2024 | 2024-11-12 | $-1.340 | $-1.380 | 2.90% | 104.76M |
| Q2/2024 | 2024-08-05 | $-1.240 | $-1.300 | 4.62% | 87.17M |
| Q1/2024 | 2024-05-06 | $-1.090 | $-1.200 | 9.17% | 75.00M |
| Q4/2023 | 2024-02-20 | $-0.730 | $-1.210 | 39.67% | 71.53M |
Analyst view
Analyst targets
Consensus
$262.38
Median
$259.50
Low
$200.00
High
$380.00
Recent target updates
News flow
Latest company news
Market coverage
globenewswire.com Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month Jun 18, 2026 fool.com 3 Under-the-Radar Stocks to Buy and Hold for a Decade Jun 16, 2026 globenewswire.com Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026 Jun 15, 2026 seekingalpha.com Axsome Therapeutics, Inc. (AXSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript Jun 8, 2026Company releases
Company context
Company profile
Bolsa:
NASDAQ
Sector:
Healthcare
Industria:
Biotechnology
Currency
USD
Axsome Therapeutics Inc is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system CNS disorders within the United States Its robust product pipeline features several promising candidates including AXS05 an investigational therapy currently being developed for major depressive disorder and treatmentresistant depression This compound is also in Phase III clinical evaluation for Alzheimers disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation AXS07 a novel orally administered rapidlyacting investigational medicine that employs multiple mechanisms of action It has concluded two Phase III studies for the acute treatment of migraine attacks AXS12 a selective and potent norepinephrine reuptake inhibitor which is presently undergoing a Phase III trial for narcolepsy AXS14 an oral investigational drug advancing through Phase III trials for the management of fibromyalgia Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS05s potential in smoking cessation The company established in 2012 has its main offices in New York New York
Navigation